{"id":"NCT02218372","sponsor":"Astellas Pharma Europe B.V.","briefTitle":"A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","officialTitle":"A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects With Clostridium Difficile-associated Diarrhea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01-09","primaryCompletion":"2018-03-07","completion":"2018-03-07","firstPosted":"2014-08-18","resultsPosted":"2018-12-07","lastUpdate":"2024-11-26"},"enrollment":148,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Clostridium Difficile-associated Diarrhea (CDAD)"],"interventions":[{"type":"DRUG","name":"Fidaxomicin oral suspension","otherNames":["Dificid","Dificlir"]},{"type":"DRUG","name":"Fidaxomicin tablets","otherNames":["Dificlir","Dificid"]},{"type":"DRUG","name":"Vancomycin oral liquid","otherNames":[]},{"type":"DRUG","name":"Vancomycin capsules","otherNames":[]}],"arms":[{"label":"Fidaxomicin","type":"EXPERIMENTAL"},{"label":"Vancomycin","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules in pediatric participants with Clostridium difficile-associated diarrhea (CDAD). It also investigated the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin, as well as acceptance of the fidaxomicin oral suspension formulation.","primaryOutcome":{"measure":"Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days","timeFrame":"Up to day 12","effectByArm":[{"arm":"Fidaxomicin","deltaMin":77.6,"sd":null},{"arm":"Vancomycin","deltaMin":70.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":null},"locations":{"siteCount":44,"countries":["United States","Belgium","Canada","France","Germany","Hungary","Italy","Poland","Romania","Spain"]},"refs":{"pmids":["31773143","27182626"],"seeAlso":["https://astellasclinicalstudyresults.com/study.aspx?ID=362"]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":98},"commonTop":["Pyrexia","Abdominal pain","Vomiting","Diarrhoea","Headache"]}}